(Q61052949)

English

Impact of viral reactivations in the era of pre-emptive antiviral drug therapy following allogeneic haematopoietic SCT in paediatric recipients

No description defined

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

0 references

Impact of viral reactivations in the era of pre-emptive antiviral drug therapy following allogeneic haematopoietic SCT in paediatric recipients (English)

0 references

author name string

P Hiwarkar

1

0 references

H B Gaspar

2

0 references

K Gilmour

3

0 references

M Jagani

4

0 references

R Chiesa

5

0 references

N Bennett-Rees

6

0 references

J Breuer

7

0 references

K Rao

8

0 references

C Cale

9

0 references

N Goulden

10

0 references

G Davies

11

0 references

P Amrolia

12

0 references

P Veys

13

0 references

W Qasim

14

0 references

language of work or name

0 references

publication date

26 November 2012

0 references

June 2013

0 references

Bone Marrow Transplantation

0 references

48

0 references

6

0 references

803-808

0 references

803-8

0 references

The history and future of T-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.221

7 January 2021

based on heuristic

inferred from DOI database lookup

High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.221

7 January 2021

based on heuristic

inferred from DOI database lookup

Alemtuzumab (Campath-1H) in allogeneic stem cell transplantation: where do we go from here?

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.221

7 January 2021

based on heuristic

inferred from DOI database lookup

Incidence and dynamics of Epstein-Barr virus reactivation after alemtuzumab-based conditioning for allogeneic hematopoietic stem-cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.221

7 January 2021

based on heuristic

inferred from DOI database lookup

Lymphoproliferative disorders following allogeneic bone marrow transplantation: the Vancouver experience

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.221

7 January 2021

based on heuristic

inferred from DOI database lookup

Post-transplant EBV induced lymphoproliferative disorders

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.221

7 January 2021

based on heuristic

inferred from DOI database lookup

Adenovirus infections following allogeneic stem cell transplantation: incidence and outcome in relation to graft manipulation, immunosuppression, and immune recovery

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.221

7 January 2021

based on heuristic

inferred from DOI database lookup

Defining the intensity of conditioning regimens: working definitions

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.221

7 January 2021

based on heuristic

inferred from DOI database lookup

Omission of in vivo T-cell depletion promotes rapid expansion of naïve CD4+ cord blood lymphocytes and restores adaptive immunity within 2 months after unrelated cord blood transplant

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.221

7 January 2021

based on heuristic

inferred from DOI database lookup

Once daily ganciclovir as initial pre-emptive therapy delayed until threshold CMV load > or =10000 copies/ml: a safe and effective strategy for allogeneic stem cell transplant patients

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.221

7 January 2021

based on heuristic

inferred from DOI database lookup

Pre-emptive rituximab based on viraemia and T cell reconstitution: a highly effective strategy for the prevention of Epstein-Barr virus-associated lymphoproliferative disease following stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.221

7 January 2021

based on heuristic

inferred from DOI database lookup

Cytomegalovirus viral load and virus-specific immune reconstitution after peripheral blood stem cell versus bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.221

7 January 2021

based on heuristic

inferred from DOI database lookup

Increased incidence of EBV-related disease following paediatric stem cell transplantation with reduced-intensity conditioning

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.221

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of low-dose ganciclovir preemptive therapy in allogeneic haematopoietic stem cell transplant recipients compared with conventional-dose ganciclovir: a prospective observational study

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.221

7 January 2021

based on heuristic

inferred from DOI database lookup

Improved outcome for children with disseminated adenoviral infection following allogeneic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.221

7 January 2021

based on heuristic

inferred from DOI database lookup

How I treat adenovirus in hematopoietic stem cell transplant recipients

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.221

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.221

7 January 2021

based on heuristic

inferred from DOI database lookup

Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.221

7 January 2021

based on heuristic

inferred from DOI database lookup

Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.221

7 January 2021

based on heuristic

inferred from DOI database lookup

Safe adoptive transfer of virus-specific T-cell immunity for the treatment of systemic adenovirus infection after allogeneic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.221

7 January 2021

based on heuristic

inferred from DOI database lookup

Directly selected cytomegalovirus-reactive donor T cells confer rapid and safe systemic reconstitution of virus-specific immunity following stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.221

7 January 2021

based on heuristic

inferred from DOI database lookup

Capture and generation of adenovirus specific T cells for adoptive immunotherapy

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.221

7 January 2021

based on heuristic

inferred from DOI database lookup

T-cell lines specific for peptides of adenovirus hexon protein and devoid of alloreactivity against recipient cells can be obtained from HLA-haploidentical donors

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.221

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/BMT.2012.221

0 references

Dimensions Publication ID

0 references

PubMed publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q61052949&oldid=2217415127"